These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26010091)

  • 1. Liraglutide improves hypertension and metabolic perturbation in a rat model of polycystic ovarian syndrome.
    Hoang V; Bi J; Mohankumar SM; Vyas AK
    PLoS One; 2015; 10(5):e0126119. PubMed ID: 26010091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1.
    Ji S; Yang H; Ji Y; Wu W; Dong Y; Fu H; Tang N; Hou Z; Wang F
    Reprod Sci; 2024 Jul; 31(7):2049-2058. PubMed ID: 38441776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of GLP-1 Receptor Agonists in the Cardiometabolic Complications in a Rat Model of Postmenopausal PCOS.
    Torres Fernandez ED; Huffman AM; Syed M; Romero DG; Yanes Cardozo LL
    Endocrinology; 2019 Dec; 160(12):2787-2799. PubMed ID: 31593246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
    Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
    Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovarian syndrome is accompanied by repression of gene signatures associated with biosynthesis and metabolism of steroids, cholesterol and lipids.
    Salilew-Wondim D; Wang Q; Tesfaye D; Schellander K; Hoelker M; Hossain MM; Tsang BK
    J Ovarian Res; 2015 Apr; 8():24. PubMed ID: 25887459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome.
    Yanes LL; Romero DG; Moulana M; Lima R; Davis DD; Zhang H; Lockhart R; Racusen LC; Reckelhoff JF
    Gend Med; 2011 Apr; 8(2):103-15. PubMed ID: 21536229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles for the sympathetic nervous system, renal nerves, and CNS melanocortin-4 receptor in the elevated blood pressure in hyperandrogenemic female rats.
    Maranon R; Lima R; Spradley FT; do Carmo JM; Zhang H; Smith AD; Bui E; Thomas RL; Moulana M; Hall JE; Granger JP; Reckelhoff JF
    Am J Physiol Regul Integr Comp Physiol; 2015 Apr; 308(8):R708-13. PubMed ID: 25695289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.
    Pruett JE; Torres Fernandez ED; Everman SJ; Vinson RM; Davenport K; Logan MK; Ye SA; Romero DG; Yanes Cardozo LL
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic kiss1 mRNA and kisspeptin immunoreactivity are reduced in a rat model of polycystic ovary syndrome (PCOS).
    Brown RE; Wilkinson DA; Imran SA; Caraty A; Wilkinson M
    Brain Res; 2012 Jul; 1467():1-9. PubMed ID: 22668987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of DHT-Induced Hyperandrogenism on the Pro-Inflammatory Cytokines in a Rat Model of Polycystic Ovary Morphology.
    Krishnan A; Muthusami S; Periyasamy L; Stanley JA; Gopalakrishnan V; Ramachandran I
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32120970
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial.
    Nylander M; Frøssing S; Clausen HV; Kistorp C; Faber J; Skouby SO
    Reprod Biomed Online; 2017 Jul; 35(1):121-127. PubMed ID: 28479118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model.
    Ressler IB; Grayson BE; Ulrich-Lai YM; Seeley RJ
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1076-84. PubMed ID: 26078189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome.
    Mannerås L; Cajander S; Holmäng A; Seleskovic Z; Lystig T; Lönn M; Stener-Victorin E
    Endocrinology; 2007 Aug; 148(8):3781-91. PubMed ID: 17495003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of polycystic ovary syndrome.
    Patel R; Shah G
    Mol Reprod Dev; 2018 Oct; 85(10):778-789. PubMed ID: 30203897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
    Jensterle M; Kocjan T; Kravos NA; Pfeifer M; Janez A
    Endocr Res; 2015; 40(3):133-8. PubMed ID: 25330463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intense electroacupuncture normalizes insulin sensitivity, increases muscle GLUT4 content, and improves lipid profile in a rat model of polycystic ovary syndrome.
    Johansson J; Feng Y; Shao R; Lönn M; Billig H; Stener-Victorin E
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E551-9. PubMed ID: 20663984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide mends cognitive impairment by averting Notch signaling pathway overexpression in a rat model of polycystic ovary syndrome.
    Saad MA; Eltarzy MA; Abdel Salam RM; Ahmed MAE
    Life Sci; 2021 Jan; 265():118731. PubMed ID: 33160995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.